Table 2.
Total costs, health outcomes and Incremental Cost-Effectiveness Ratio.
| COST VND (USD) |
QALYs | |
|---|---|---|
| Standard treatment 1 (PD) | 314,758,471 (13,401.96) | 56.9374 |
| Standard treatment 1 + glucosamine before NSAIDs (PGD) | 348,133,295 (14,823.01) | 100.7445 |
| Standard treatment 1 + glucosamine after NSAIDs (PDG) | 339,027,398 (14,435.30) | 92.7119 |
| ICERPGD/PD VND (USD) per QALYs | 761,858 (32.44) | |
| ICERPDG/PD VND (USD) per QALYs | 678,386 (28.88) | |
| ICERPGD/PDG VND (USD) per QALYs | 1,133,615 (48.27) | |
| Standard treatment 2 (PDE) | 367,478,671 (15,646.71) | 129.8038 |
| Standard treatment 2 + glucosamine before NSAIDs (PGDE) | 443,969,715 (18,903.59) | 230.6720 |
| Standard treatment 2 + glucosamine after NSAIDs (PDEG) | 425,013,733 (18,096.47) | 211.3288 |
| ICERPDE/PD VND (USD) per QALYs | 723,519 (30.81) | |
| ICERPGDE/PDE VND (USD) per QALYs | 758,326 (32.29) | |
| ICERPDEG/PDE VND (USD) per QALYs | 705,735 (30.05) | |
| ICERPGDE/PDEG VND (USD) per QALYs | 979,981 (41.73) | |